Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses the entrepreneurial journey that took him from startup, to Big Pharma, back to startup.

Brent Vaughan talks about the differences between building a biotech and building a digital therapeutics company.

If you found a moment of tranquility during the lockdown of this pandemic, then you may have started to reflect on what’s really important — at home and the office. I recently found myself pondering the concept of corporate culture.

Biomanufacturing icon Andy Skibo, and Life Science Leader chief editor Rob Wright, on topics and planning for upcoming fireside chat at the American Biomanufacturing Summit 2020 that has now gone virtual.

Life Science Leader’s Rob Wright provides perspective on BIO Digital 2020, and a recommendation for the session every BIO Digital registered attendee should make time to attend. 

Carol Lynch, president of Sandoz U.S. and head of North America, fields biosimilars-related questions from the audience at the 2020 BIO CEO & Investor Conference. 

Chief Editor Rob Wright reminisces about his days as a pharma rep and the value of in-person meetings vs. today’s virtual interactions.

Professor Ugur Sahin, M.D., Ph.D. never wanted to be an entrepreneur. Yet, today he’s the cofounder and CEO of BioNTech, a publicly traded German biotech aspiring to develop individualized cancer medicines. It was a surprising career path switch.

Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses how his company pivoted as a result of the current pandemic, including announced efforts to develop a vaccine for COVID-19.